Zymeworks Debt to Equity Ratio 2016-2022 | ZYME
Current and historical debt to equity ratio values for Zymeworks (ZYME) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Zymeworks debt/equity for the three months ending June 30, 2022 was 0.00.
| Zymeworks Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-06-30 |
$0.15B |
$0.22B |
0.66 |
| 2022-03-31 |
$0.15B |
$0.28B |
0.52 |
| 2021-12-31 |
$0.14B |
$0.25B |
0.56 |
| 2021-09-30 |
$0.14B |
$0.28B |
0.51 |
| 2021-06-30 |
$0.15B |
$0.32B |
0.47 |
| 2021-03-31 |
$0.11B |
$0.38B |
0.30 |
| 2020-12-31 |
$0.13B |
$0.41B |
0.31 |
| 2020-09-30 |
$0.14B |
$0.43B |
0.32 |
| 2020-06-30 |
$0.12B |
$0.49B |
0.24 |
| 2020-03-31 |
$0.11B |
$0.52B |
0.22 |
| 2019-12-31 |
$0.12B |
$0.25B |
0.50 |
| 2019-09-30 |
$0.09B |
$0.31B |
0.29 |
| 2019-06-30 |
$0.08B |
$0.33B |
0.24 |
| 2019-03-31 |
$0.07B |
$0.17B |
0.40 |
| 2018-12-31 |
$0.06B |
$0.18B |
0.36 |
| 2018-09-30 |
$0.03B |
$0.17B |
0.15 |
| 2018-06-30 |
$0.03B |
$0.19B |
0.13 |
| 2018-03-31 |
$0.02B |
$0.10B |
0.20 |
| 2017-12-31 |
$0.02B |
$0.12B |
0.13 |
| 2017-09-30 |
$0.02B |
$0.08B |
0.21 |
| 2017-06-30 |
$0.02B |
$0.10B |
0.18 |
| 2017-03-31 |
$0.03B |
$0.05B |
0.61 |
| 2016-12-31 |
$0.03B |
$0.07B |
0.39 |
| 2016-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2016-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2015-12-31 |
$0.01B |
$0.02B |
0.27 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.529B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
